A5060814129- Liver Diseases and Immunity
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Pediatric Hepatobiliary Diseases and Treatments
- Hepatitis B Virus Studies
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- Eosinophilic Esophagitis
- SARS-CoV-2 and COVID-19 Research
- Liver physiology and pathology
- Inflammatory Bowel Disease
- Pancreatitis Pathology and Treatment
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Medical and Health Sciences Research
- Liver Disease and Transplantation
- Gallbladder and Bile Duct Disorders
- Diabetes and associated disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Celiac Disease Research and Management
- T-cell and B-cell Immunology
- Drug-Induced Hepatotoxicity and Protection
University Medical Center Hamburg-Eppendorf
2016-2025
Universität Hamburg
2016-2025
ERN RARE-LIVER
2022-2024
Eppendorf (Belgium)
2023
Demos
2023
Abstract Background/Aims In this observational study, we explored the humoral and cellular immune response to SARS‐CoV‐2 vaccination in patients with autoimmune hepatitis (AIH) cholestatic liver disease (primary sclerosing cholangitis [PSC] primary biliary [PBC]). Methods Anti‐SARS‐CoV‐2 antibody titers were determined using DiaSorin LIAISON Roche immunoassays 103 AIH, 64 PSC, 61 PBC 95 healthy controls >14 days after second COVID‐19 vaccination. The spike‐specific T‐cell was assessed an...
Abstract Type 2 innate lymphoid cells (ILC2) mediate inflammatory immune responses in the context of diseases triggered by alarmin IL-33. In recent years, IL-33 has been implicated pathogenesis immune-mediated liver diseases. However, immunoregulatory function ILC2s inflamed remains elusive. Using murine model Con A–induced hepatitis, we showed that selective expansion was associated with highly elevated hepatic expression, severe inflammation, and infiltration eosinophils. CD4+ T...
In immune-mediated hepatitis, type 2 innate lymphoid cells (ILC2) as well effector CD4+ T have been shown to drive disease pathology. However, less is known about mechanisms involved in the regulation of ILC2 function during liver inflammation. We showed that homeostasis, hepatic constituted a very small population with naive, inactive phenotype. During cytokines IL-33 and IFNγ were expressed tissue. induced strong activation expression IL-6 by while suppressed cytokine production....
To explore the humoral and T-cell response to third COVID-19 vaccination in autoimmune hepatitis (AIH).Anti-SARS-CoV-2 antibody titers were prospectively determined 81 AIH patients 53 healthy age- sex-matched controls >7 days (median 35) after first booster vaccination. The spike-specific was assessed using an activation-induced marker assay (AIM) a subset of patients.Median levels significantly lower compared (10 908 vs. 25 000 AU/ml, p < .001), especially treated with MMF (N = 14, 4542...
There is little data on the hepatic efficacy and safety of immunomodulatory drugs used in patients with autoimmune hepatitis (AIH), despite their established use dermatology, rheumatology inflammatory bowel diseases (IBD). Our aim was to collect real-life experience expert centres treating AIH these drugs, considered unconventional for management.
Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease of unknown pathogenesis, with a high risk to develop cirrhosis and malignancies. Functional dysregulation T cells association genetic polymorphisms in cell-related genes were previously reported for PSC. Here, we genotyped representative PSC cohort several disease-associated loci identified rs56258221 (BACH2/MIR4464) correlate not only the peripheral blood cell immunophenotype but also functional capacities naive CD4+...
Primary sclerosing cholangitis (PSC) is a chronic heterogenous cholangiopathy with unknown etiology where inflammation of the bile ducts leads to multifocal biliary strictures and fibrosis consecutive cirrhosis development. We here aimed identify PSC-specific gene signature associated performed RNA-sequencing 47 liver biopsies from people PSC (n = 16), primary (PBC, n 15), metabolic dysfunction-associated steatotic disease (MASLD, 16) different stages progression. For validation, we compared...
Variant syndromes of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) share diagnostic features both entities, but their immunological underpinnings remain largely unexplored.We performed blood profiling 23 soluble immune markers immunogenetics in a cohort 88 patients with liver diseases (29 typical AIH, 31 PBC 28 clinically PBC/AIH variant syndromes). The association demographical, serological clinical was analyzed.While T B cell receptor repertoires were highly skewed...
Concurrent fatty liver disease represents an emerging challenge in the care of individuals with autoimmune diseases (AILD). Therefore, we aimed to validate ultrasound-based method controlled-attenuation parameter (CAP) as a non-invasive tool detect hepatic steatosis AILD.The diagnostic performance CAP determine biopsy-proven (>5%) was assessed AILD (autoimmune hepatitis [AIH], primary biliary cholangitis [PBC], [PSC], or variant syndromes) who underwent biopsy at University Medical Center...
Die primär biliäre Cholangitis (PBC) ist eine chronische cholestatische Lebererkrankung, die unbehandelt zur Leberzirrhose fortschreiten kann. frühzeitige Diagnosestellung, Therapieeinleitung und gegebenenfalls Therapieanpassung daher essenziell, um Krankheitsprogression zu verhindern. Bewertung eines ausreichenden Therapieansprechens kann im klinischen Alltag Herausforderung darstellen, da Zeitpunkt Grenzwerte Therapieevaluation in der Literatur uneinheitlich definiert sind. Neben...
Zu den autoimmunen Lebererkrankungen gehören die autoimmune Hepatitis (AIH), primär biliäre Cholangitis (PBC) und sklerosierende (PSC). Diagnostik, Therapie Surveillance dieser Erkrankungen sind aufwendig. Dieser Beitrag widmet sich der Versorgung mit dem Fokus auf neue klinische Aspekte über kondensierte Darstellung aktuellen leitliniengerechten hinaus.
Aims/Background Patients with autoimmune hepatitis (AIH) require immunosuppressive treatment, which might impair the immune response to vaccination. In this prospective cohort study, we assessed humoral of AIH patients SARS-CoV-2
Im 1. Teil der Reihe „Autoimmune Lebererkrankungen – ein Update (Teil 1)“ wurden die Grundlagen zur Diagnostik und Surveillance autoimmuner autoimmune Hepatitis (AIH) behandelt In diesem 2. werden mit primär biliären Cholangitis (PBC) sklerosierenden (PSC) cholestatische beleuchtet.
Liver stiffness is an important surrogate marker for liver fibrosis and the presence of clinically significant portal hypertension (CSPH). However, a impact pronounced inflammation especially in autoimmune hepatitis (AIH) or cholestasis primary sclerosing cholangitis (PSC) on values risk false positive results has been demonstrated past. We hypothesise that spleen elastography can improve diagnosing CSPH patients with AILD.
Background and Aims The pathogenesis of Primary sclerosing cholangitis (PSC) is still unknown. Intrahepatic naive-like T cell population prone to polarize towards TH17 phenotype several polymorphisms in immune-related genes has been linked PSC. We hypothesized that genetic predisposition contributing patients with
Type 2 innate lymphoid cells (ILC2 s) are activated by IL-33 and mediate immune responses expression of the cytokines IL-5 IL-13. During Concanavalin (Con)A-induced immune-mediated hepatitis, effector CD4 T hepatic ILC2 s drive liver inflammation. However, less is known about mechanisms involved in regulation function during We aim at investigating phenotype its modulation plasticity triggered inflammation-induced cytokines. also study mutual influence mediated cells.
Background Genome-wide association studies (GWAS) associated primary sclerosing cholangitis (PSC) to several polymorphisms in immune-related genes. We here addressed the question whether specific may affect T cell differentiation, immune phenotype and clinical course of patients with PSC.